A Phase 1 interventional study of K-808 in Primary Biliary Cholangitis and Compensated Cirrhosis, sponsored by Kowa Research Institute, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 53rd largest by enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2024, is one of 7 in phase 1, and was the 74th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
Ipsen · Sites in United States
Women only
Zydus Therapeutics Inc. · Sites in United States
Ages 18+
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 18 · Phase 4 3
First in 1994; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 46 across the 65 interventional studies, 430 across the 17 observational. Of the 61 that completed or were terminated, 33 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Institute, Inc., one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Kowa Company, Ltd. has 2 studies filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis, Biliary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06427395Phase 3Zydus Therapeutics Inc.Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | 2027-04-18 |
| NCT06825559Zydus Therapeutics Inc.Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | 2026-12-31 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07631442Stanford UniversityUsing Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC) | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has a PBC diagnosis as demonstrated by the presence of ≥2 of the following three diagnostic criteria (Lindor et al, 2019; Hirschfield et al, 2017):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
K-808 single dose followed by multiple-dose treatment period.
Drug: K-808
K-808 single dose followed by optional multiple-dose treatment period.
Drug: K-808
K-808 single or multi dose extended-release tablets
Also known as: Pemafibrate
PK parameters after a single dose of K-808: Area under the curve from 0 to infinity (AUC0-inf)
Time frame: Day 1 - Day 3
PK parameters after a single dose of K-808: Area under the curve from time 0 to last quantifiable time (AUC0-t)
Time frame: Day 1 to Day 3
PK parameters after a single dose of K-808: Observed maximum plasma concentration (Cmax)
Time frame: Day 1 to Day 3
PK parameters after a single dose of K-808: Time to reach observed maximum plasma concentration (Tmax)
Time frame: Day 1 to Day 3
PK parameters after a single dose of K-808: kel
Time frame: Day 1 to Day 3
PK parameters after a single dose of K-808: Apparent first-order terminal elimination half-life (t½)
Time frame: Day 1 to Day 3.
PK parameters after a single dose of K-808: Apparent total volume of distribution estimated based on the terminal phase (Vd/F)
Time frame: Day 1 to Day 3
PK parameters after a single dose of K-808: Apparent plasma clearance after extravascular administration (CL/F)
Time frame: Day 1 to Day 3
PK parameters after a single dose of K-808: Mean resistance time from time 0 to last measurable concentration (MRT0-t)
Time frame: Day 1 to Day 3
PK parameters after a single dose of K-808: MRT from time 0 extrapolated to infinity (MRT0-inf)
Time frame: Day 1 to Day 3
Trough concentrations after multiple dosing of K-808
Time frame: Day 4 - Day 6
PK parameters at steady state after multiple dosing of K-808: Area under the curve over the dosing interval (AUC0-tau)
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: Cmax
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: Tmax
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: kel
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: t½
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: Vd,ss/F at steady state
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: CLss/F at steady state
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: MRT at steady state (MRTss)
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: Observed accumulation ratio based on the AUC (RobsAUC)
Time frame: Day 6 to Day 8
PK parameters of K-808 metabolites after a single dose: AUC0-inf
Time frame: Day 1 - Day 3
PK parameters of K-808 metabolites after a single dose: AUC0-t
Time frame: Day 1 to Day 3
PK parameters of K-808 metabolites after a single dose: Cmax
Time frame: Day 1 to Day 3
PK parameters of K-808 metabolites after a single dose: Tmax
Time frame: Day 1 to Day 3
PK parameters of K-808 metabolites after a single dose: kel
Time frame: Day 1 to Day 3
PK parameters of K-808 metabolites after a single dose: t½
Time frame: Day 1 to Day 3
PK parameters of K-808 metabolites after a single dose: MRT0-t
Time frame: Day 1 to Day 3
PK parameters of K-808 metabolites after a single dose: MRT0-inf
Time frame: Day 1 to Day 3
PK parameters at steady state after multiple dosing of K-808: AUC0- tau
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: Cmax
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: Tmax
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: kel
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: t½
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: (MRTss)
Time frame: Day 6 to Day 8
PK parameters at steady state after multiple dosing of K-808: (RobsAUC)
Time frame: Day 6 to Day 8
Trough concentrations after multiple dosing of K-808
Time frame: Day 4 to Day 6
To assess the safety and tolerability of K-808
Time frame: 5 Weeks
Ran from Oct 2024 to primary completion in Mar 2025, 5 months.
Of 15 phase 1 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemafibrate
Kowa Research Institute, Inc. →